---
document_datetime: 2025-12-02 05:08:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sepioglin.html
document_name: sepioglin.html
version: success
processing_time: 0.119449
conversion_datetime: 2025-12-27 17:47:42.607389
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sepioglin

[RSS](/en/individual-human-medicine.xml/66721)

##### Withdrawn

This medicine's authorisation has been withdrawn

pioglitazone Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 March 2012, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Sepioglin, (pioglitazone), which had been approved for treatment of type 2 diabetes mellitus. The marketing authorisation holder (MAH) responsible for Sepioglin was Vaia S.A..

On 6 June 2013, the European Commission issued a decision to withdraw the marketing authorisation for Sepioglin, following its receipt of a letter dated 22 May 2013 notifying the Commission of the MAH's decision to voluntarily withdraw the marketing authorisation for this product for commercial reasons. Sepioglin has not been marketed in any European country.

Pursuant to this decision, the European public assessment report for Sepioglin is updated to reflect that the marketing authorisation is no longer valid.

Sepioglin : EPAR - Summary for the public

English (EN) (516.9 KB - PDF)

**First published:** 23/04/2012

**Last updated:** 18/07/2013

[View](/en/documents/overview/sepioglin-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-773)

български (BG) (588.38 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/bg/documents/overview/sepioglin-epar-summary-public_bg.pdf)

español (ES) (521.09 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/es/documents/overview/sepioglin-epar-summary-public_es.pdf)

čeština (CS) (586.86 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/cs/documents/overview/sepioglin-epar-summary-public_cs.pdf)

dansk (DA) (521.07 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/da/documents/overview/sepioglin-epar-summary-public_da.pdf)

Deutsch (DE) (523.81 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/de/documents/overview/sepioglin-epar-summary-public_de.pdf)

eesti keel (ET) (532.38 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/et/documents/overview/sepioglin-epar-summary-public_et.pdf)

ελληνικά (EL) (624.77 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/el/documents/overview/sepioglin-epar-summary-public_el.pdf)

français (FR) (523.97 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fr/documents/overview/sepioglin-epar-summary-public_fr.pdf)

italiano (IT) (520.94 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/it/documents/overview/sepioglin-epar-summary-public_it.pdf)

latviešu valoda (LV) (574.59 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lv/documents/overview/sepioglin-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (544.48 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lt/documents/overview/sepioglin-epar-summary-public_lt.pdf)

magyar (HU) (581.43 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/hu/documents/overview/sepioglin-epar-summary-public_hu.pdf)

Malti (MT) (571.75 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/mt/documents/overview/sepioglin-epar-summary-public_mt.pdf)

Nederlands (NL) (582.92 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/nl/documents/overview/sepioglin-epar-summary-public_nl.pdf)

polski (PL) (587.23 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pl/documents/overview/sepioglin-epar-summary-public_pl.pdf)

português (PT) (520.46 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pt/documents/overview/sepioglin-epar-summary-public_pt.pdf)

română (RO) (608.16 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/ro/documents/overview/sepioglin-epar-summary-public_ro.pdf)

slovenčina (SK) (568.74 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sk/documents/overview/sepioglin-epar-summary-public_sk.pdf)

slovenščina (SL) (566.23 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sl/documents/overview/sepioglin-epar-summary-public_sl.pdf)

Suomi (FI) (519.46 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fi/documents/overview/sepioglin-epar-summary-public_fi.pdf)

svenska (SV) (517.5 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sv/documents/overview/sepioglin-epar-summary-public_sv.pdf)

## Product information

Sepioglin : EPAR - Product Information

English (EN) (1.04 MB - PDF)

**First published:** 23/04/2012

**Last updated:** 18/07/2013

[View](/en/documents/product-information/sepioglin-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-203)

български (BG) (2.44 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/bg/documents/product-information/sepioglin-epar-product-information_bg.pdf)

español (ES) (1.12 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/es/documents/product-information/sepioglin-epar-product-information_es.pdf)

čeština (CS) (2.05 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/cs/documents/product-information/sepioglin-epar-product-information_cs.pdf)

dansk (DA) (1.04 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/da/documents/product-information/sepioglin-epar-product-information_da.pdf)

Deutsch (DE) (1.13 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/de/documents/product-information/sepioglin-epar-product-information_de.pdf)

eesti keel (ET) (1.05 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/et/documents/product-information/sepioglin-epar-product-information_et.pdf)

ελληνικά (EL) (3 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/el/documents/product-information/sepioglin-epar-product-information_el.pdf)

français (FR) (1.13 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fr/documents/product-information/sepioglin-epar-product-information_fr.pdf)

íslenska (IS) (1.05 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/is/documents/product-information/sepioglin-epar-product-information_is.pdf)

italiano (IT) (1.11 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/it/documents/product-information/sepioglin-epar-product-information_it.pdf)

latviešu valoda (LV) (2.21 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lv/documents/product-information/sepioglin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.29 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lt/documents/product-information/sepioglin-epar-product-information_lt.pdf)

magyar (HU) (2.03 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/hu/documents/product-information/sepioglin-epar-product-information_hu.pdf)

Malti (MT) (2.15 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/mt/documents/product-information/sepioglin-epar-product-information_mt.pdf)

Nederlands (NL) (1.03 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/nl/documents/product-information/sepioglin-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/no/documents/product-information/sepioglin-epar-product-information_no.pdf)

polski (PL) (2.27 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pl/documents/product-information/sepioglin-epar-product-information_pl.pdf)

português (PT) (1.06 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pt/documents/product-information/sepioglin-epar-product-information_pt.pdf)

română (RO) (1.39 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/ro/documents/product-information/sepioglin-epar-product-information_ro.pdf)

slovenčina (SK) (2.09 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sk/documents/product-information/sepioglin-epar-product-information_sk.pdf)

slovenščina (SL) (2.09 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sl/documents/product-information/sepioglin-epar-product-information_sl.pdf)

Suomi (FI) (1.03 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fi/documents/product-information/sepioglin-epar-product-information_fi.pdf)

svenska (SV) (1.16 MB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sv/documents/product-information/sepioglin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** - 06/06/2013

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sepioglin : EPAR - All Authorised presentations

English (EN) (481.52 KB - PDF)

**First published:** 23/04/2012

**Last updated:** 18/07/2013

[View](/en/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-275)

български (BG) (531.82 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/bg/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_bg.pdf)

español (ES) (482.88 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/es/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (521.02 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/cs/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (483.47 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/da/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (483.73 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/de/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (484.53 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/et/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (532.36 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/el/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_el.pdf)

français (FR) (484.51 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fr/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (499.82 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/is/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_is.pdf)

italiano (IT) (481.45 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/it/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (521.53 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lv/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (515.54 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lt/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (531.8 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/hu/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (522.04 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/mt/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (484.87 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/nl/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (498.24 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/no/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_no.pdf)

polski (PL) (508.14 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pl/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_pl.pdf)

português (PT) (481.5 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pt/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_pt.pdf)

română (RO) (511.43 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/ro/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (538.22 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sk/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (489.21 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sl/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (485.7 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fi/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (480.76 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sv/documents/all-authorised-presentations/sepioglin-epar-all-authorised-presentations_sv.pdf)

Sepioglin : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (482.12 KB - PDF)

**First published:** 23/04/2012

**Last updated:** 18/07/2013

[View](/en/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-369)

български (BG) (568.65 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/bg/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (487.13 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/es/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (581.74 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/cs/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (481.43 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/da/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (488.65 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/de/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (481.58 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/et/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (582.94 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/el/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (488.45 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fr/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (482.43 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/is/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (494.77 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/it/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (591.51 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lv/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (559.35 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/lt/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (572.32 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/hu/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (583.35 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/mt/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (486.69 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/nl/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (483.72 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/no/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (584 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pl/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (481.46 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/pt/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (556.25 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/ro/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (578.93 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sk/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (577.73 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sl/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (480.79 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/fi/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (482.26 KB - PDF)

**First published:**

23/04/2012

**Last updated:**

18/07/2013

[View](/sv/documents/conditions-member-states/sepioglin-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Sepioglin Active substance pioglitazone hydrochloride International non-proprietary name (INN) or common name pioglitazone Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BG03

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Pioglitazone is indicated as second- or third-line treatment of type-2 diabetes mellitus as described below:

**as monotherapy:**

- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;

**as dual oral therapy in combination with:**

- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;

**as triple oral therapy in combination with:**

- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Pioglitazone is also indicated for combination with insulin in type-2-diabetes-mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).

After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).

## Authorisation details

EMA product number EMEA/H/C/002021

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Vaia S.A.

1, 28 Octovriou Str.

Marketing authorisation issued 09/03/2012 Withdrawal of marketing authorisation 06/06/2013 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sepioglin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (523.11 KB - PDF)

**First published:** 18/07/2013

**Last updated:** 18/07/2013

[View](/en/documents/procedural-steps-after/sepioglin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Sepioglin : EPAR - Public assessment report

Reference Number: EMA/207581/2012

English (EN) (818.82 KB - PDF)

**First published:** 23/04/2012

**Last updated:** 18/07/2013

[View](/en/documents/assessment-report/sepioglin-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sepioglin

Adopted

Reference Number: EMA/CHMP/644013/2011

English (EN) (520.68 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 18/07/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sepioglin_en.pdf)

**This page was last updated on** 18/07/2013

## Share this page

[Back to top](#main-content)